Tibsovo
Abbott PCR Test Gets FDA Approval as CDx for Servier's Tibsovo for Rare Blood Cancer
The drug and test were approved for patients with relapsed or refractory myelodysplastic syndromes.
The drug and test were approved for patients with relapsed or refractory myelodysplastic syndromes.